^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

TVI-Brain-1

i
Other names: TVI-Brain-1
Associations
Company:
TVAX Biomedical
Drug class:
Immunostimulant
Related drugs:
Associations
4ms
TVI-AST-008: Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) (clinicaltrials.gov)
P2/3, N=120, Recruiting, TVAX Biomedical | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
temozolomide • TVI-Brain-1
11ms
Trial completion date • Trial primary completion date
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
temozolomide • TVI-Brain-1
1year
Phase classification
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
temozolomide • TVI-Brain-1
1year
Enrollment open
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
temozolomide • TVI-Brain-1
over1year
Trial initiation date
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
temozolomide • TVI-Brain-1
over1year
New trial
|
TVI-Brain-1
over1year
Enrollment change
|
TVI-Brain-1
over1year
Trial initiation date
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
temozolomide • TVI-Brain-1
almost2years
New P2b trial
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
temozolomide • TVI-Brain-1